Loading…
Loading…
EQUITY / NYSE · XASE
Apimeds Pharmaceuticals US, Inc
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗3.25 USD · 0.9317%
Observed: Oct 2, 2026, 10:09 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 3.22 USD · Volume 134,584
20 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -6,278,760 USD | -2,663,904 USD | — |
| Net income | -20,173,129 USD | -2,662,193 USD | — |
| Cash and cash equivalents | 278,371 USD | 8,735,323 USD | -96.81% |
| Total liabilities | 21,175,156 USD | — | — |
| Total equity | 106,448,541 USD | 9,737,679 USD | +993.16% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 278,371 USD | — | — | 1,636,655 USD | 1,636,655 USD | 6,986,617 USD | — | 8,735,323 USD |
| Net incomeIncome statement | -20,173,129 USD | -55,232,982 USD | -35,059,852 USD | — | -6,001,137 USD | -1,781,255 USD | -4,845,845 USD | -2,662,193 USD |
| Operating profitIncome statement | -6,278,760 USD | -18,464,454 USD | — | — | -11,912,562 USD | -1,844,239 USD | -4,872,511 USD | -2,663,904 USD |
| Total assetsBalance sheet | 127,623,697 USD | — | — | 164,183,736 USD | 164,183,736 USD | 9,250,036 USD | — | — |
| Total equityBalance sheet | 106,448,541 USD | — | 126,515,459 USD | 153,347,827 USD | 153,347,827 USD | 8,160,652 USD | — | 9,737,679 USD |
| Total liabilitiesBalance sheet | 21,175,156 USD | — | — | 10,835,909 USD | 10,835,909 USD | 1,089,384 USD | — | — |
| Capital expendituresCash flow statement | — | 9,394 USD | — | — | 57,333 USD | — | 35,909 USD | — |
| Financing cash flowCash flow statement | — | 4,386,002 USD | — | — | 20,619,327 USD | — | 12,126,646 USD | — |
| Investing cash flowCash flow statement | — | 1,990,606 USD | — | — | -10,060,351 USD | — | -35,909 USD | — |
| Operating cash flowCash flow statement | — | -7,734,893 USD | — | — | -8,925,777 USD | — | -5,107,575 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 05/04/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.